Archives

Evergreen Nephrology and Partners Demonstrate Strong Patient Outcomes and Cost Savings in Medicare’s 2024 Kidney Care Choices Program

B Over $40 million in Medicare savings emphasizes Evergreen’s role in improving care for patients with advanced kidney disease NASHVILLE, Tenn., April 22, 2026 /PRNewswire/… Login to continue reading Login…

Read MoreEvergreen Nephrology and Partners Demonstrate Strong Patient Outcomes and Cost Savings in Medicare’s 2024 Kidney Care Choices Program

Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients

B CARY, N.C., April 22, 2026 /PRNewswire/ — Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced today that pegrizeprument… Login to continue reading Login…

Read MorePegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients